Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31294147 | 1.00 | EPHX1 (0.46) | EPHX1SMN1; SMN2EPHX2LMNAALDH1A1 | |
| SCHEMBL14605829 | 1.00 | EPHX1 (0.46) | EPHX1SMN1; SMN2EPHX2LMNAALDH1A1 | |
| SCHEMBL16439945 | 0.98 | EPHX1 (0.45) | EPHX1SMN1; SMN2EPHX2LMNAALDH1A1 | |
| SCHEMBL16440016 | 0.98 | EPHX1 (0.45) | EPHX1SMN1; SMN2EPHX2LMNAALDH1A1 | |
| SCHEMBL16439906 | 0.98 | EPHX1 (0.45) | EPHX1SMN1; SMN2EPHX2LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL31294335 | 0.98 | EPHX1 (0.45) | EPHX1SMN1; SMN2EPHX2LMNAALDH1A1 | |
| SCHEMBL10319950 | 0.98 | LMNA (0.44) | EPHX1SMN1; SMN2EPHX2LMNAALDH1A1 | |
| SCHEMBL10321971 | 0.98 | LMNA (0.44) | EPHX1SMN1; SMN2EPHX2LMNAALDH1A1 | |
| SCHEMBL1288426 | 0.98 | LMNA (0.44) | EPHX1SMN1; SMN2EPHX2LMNAALDH1A1 | |
| SCHEMBL16439941 | 0.96 | LMNA (0.43) | EPHX1SMN1; SMN2EPHX2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118812380-A | Synthesis method of chiral beta-methylcyclohexyl alanine | 吉尔多肽生物制药(大连市)有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-118812380-A | Synthesis method of chiral beta-methylcyclohexyl alanine | 吉尔多肽生物制药(大连市)有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118812380-A | Synthesis method of chiral beta-methylcyclohexyl alanine | 吉尔多肽生物制药(大连市)有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118812380-A | Synthesis method of chiral beta-methylcyclohexyl alanine | 吉尔多肽生物制药(大连市)有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024083220-A1 | LIGAND-OLIGONUCLEOTIDE CONJUGATE AND LINKER FOR CONJUGATE | 上海京新生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-114853866-A | Peptidomimetic macrocycles | 艾瑞朗医疗公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-112500466-B | Peptidomimetic macrocycles | 艾瑞朗医疗公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-108348571-B | Peptidomimetic macrocycles and uses thereof | 艾瑞朗医疗公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114173878-A | Peptidomimetic macrocycles and uses thereof | 艾瑞朗医疗公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20050203080-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050182046-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2005-08-18 | — | — | US | disclosed |
| US-6683075-B1 | FUSED NITROGENHETEROCYCLIC AMIDES; ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667305-B1 | Alzheimer's disease; beta-amyloid peptide is a small fragment of the amyloid precursor protein | ATHENA NEUROSCIENCES, INC. | 2003-12-23 | — | — | US | disclosed |
| US-6653303-B1 | Fused nitroheterocycle with amino and amido functionality; inhibiting beta-amyloid peptide release and/or synthesis; Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-11-25 | — | — | US | disclosed |
| US-6635632-B1 | Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-10-21 | — | — | US | disclosed |
| US-6632811-B2 | Administering cycloalkyl, lactam, lactone compounds for for inhibiting beta -amyloid peptide release and/or its synthesis in a cell | ATHENA NEUROSCIENCES, INC. | 2003-10-14 | — | — | US | disclosed |
| US-6559141-B2 | Inhibit beta-amyloid peptide release and/or synthesis, use in treating Alzheimer's disease; for example, 5-(N'-(phenylacetyl)-L-alpha-(2-thienyl)glycinyl)-amino-7-methyl-5,7-dihydro-6H-dibenz(b, d)azepin-6-one | ATHENA NEUROSCIENCES, INC. | 2003-05-06 | — | — | US | disclosed |
| US-6544978-B2 | Treating Alzheimer's disease both prophylactically and therapeutically | ATHENA NEUROSCIENCES, INC. | 2003-04-08 | — | — | US | disclosed |
| US-6541466-B2 | Such as 1-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)-aminodibenzosuberane; for treatment of Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203080-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | EPHX1 1406/4885SMN1; SMN2 2315/4885EPHX2 1364/4885 |
| US-20050182046-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | EPHX1 1406/4885SMN1; SMN2 2315/4885EPHX2 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.